Tissue distribution, metabolism and excretion of paclitaxel in mice

Alex Sparreboom(The Ohio State University), Jos H. Beijnen(The Netherlands Cancer Institute), Olaf van Tellingen(Dutch Cancer Society), Willem J. Nooijen(The Netherlands Cancer Institute)
Anti-Cancer Drugs
January 1, 1996
10.1097/00001813-199601000-00009
Cited by 129

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884